Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Recruiting	Phase 1 / Phase 2	2026-07-21		NCT06088771

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Icahn School of Medicine at Mount Sinai	256

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Icahn School of Medicine at Mount Sinai	New York	United States	342

Clinical trials